Prolacta Clinical Advisory Board Members Present Webinar on Improved Growth Metrics for Preterm Infants Fed an Exclusive Human Milk Diet
DUARTE, Calif., Dec. 1, 2022 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced today that two members of the Prolacta Clinical Advisory Board (PCAB) will present a webinar for clinicians who care for preterm infants titled "Improved Growth Metrics for Preterm Infants Supported With a Human Milk Diet" on Thursday, Dec. 1, at 9 a.m. PT.
- Stacia Pegram, MA, RDN, LD, and Patti Perks, MS, RDN, CNSC, will present "Improved Growth Metrics for Preterm Infants Supported With a Human Milk Diet" on Dec. 1
DUARTE, Calif., Dec. 1, 2022 /PRNewswire/ -- Prolacta Bioscience , the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced today that two members of the Prolacta Clinical Advisory Board (PCAB) will present a webinar for clinicians who care for preterm infants titled "Improved Growth Metrics for Preterm Infants Supported With a Human Milk Diet" on Thursday, Dec. 1, at 9 a.m. PT. - Perks and Pegram are members of the Prolacta Clinical Advisory Board (PCAB), a group of neonatologists, neonatal nursing leaders, and neonatal dietitians with broadly recognized clinical expertise.
- Prolacta's 100% human milk-based nutritional products have been evaluated in more than 20 clinical studies published in peer-reviewed journals.
- Prolacta maintains the industry's strictest quality and safety standards for screening, testing, and processing donor human milk.